Whipplewood Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.91K Sell
23
-265
-92% -$34.9K ﹤0.01% 374
2026
Q1
$40.1K Buy
288
+282
+4,700% +$39.5K 0.02% 296
2025
Q4
$736 Buy
+6
New +$729 ﹤0.01% 437
2025
Q3
Sell
-385
Closed -$42.7K 652
2025
Q2
$42.7K Hold
385
0.02% 343
2025
Q1
$41.9K Buy
385
+9
+2% +$929 0.02% 331
2024
Q4
$34.7K Buy
+376
New +$33.9K 0.02% 366

Other funds holding GILD

Whipplewood Advisors's GILD Position: Q2 2026 in Review

Whipplewood Advisors reduced its Gilead Sciences (GILD) stake by 92% in Q2 2026, selling an estimated $34.9K and leaving 23 shares worth $2.91K. The position accounts for ﹤0.01% of the portfolio, ranked #374.

Whipplewood Advisors first reported a position in GILD in Q4 2024 and has held it in 6 quarters since. The position peaked at $42.7K in Q2 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Whipplewood Advisors held 23 shares of Gilead Sciences worth $2.91K as of Q2 2026.
  • Whipplewood Advisors sold 265 Gilead Sciences shares in Q2 2026, an estimated $34.9K.
  • Gilead Sciences made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #374 holding.
  • Whipplewood Advisors first reported a position in Gilead Sciences in Q4 2024 and has held it in 6 quarters since.
  • Whipplewood Advisors's Gilead Sciences position peaked at $42.7K in Q2 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.